This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Care Funds That Can Continue Rallying

NEW YORK ( TheStreet) -- Health stocks have been rallying. During the past year, the average health mutual fund returned 23.9%, while the S&P 500 gained 12.3%, according to Morningstar. Biotech stocks have been especially strong performers. With many companies winning drug approvals, Fidelity Select Biotechnology (FBIOX) returned 43.1% in the past year.

Can the health stocks remain market favorites? Probably. The outlook for sales and earnings is strong. If President Obama wins reelection, his signature health reform legislation will proceed, offering insurance coverage to 30 million people. That will provide new customers for hospitals and pharmaceutical companies.

If Gov. Romney wins, the implementation of Obamacare could slow. But chances are that the Republicans will not be able to stop the program altogether. Recent polls suggest that Democrats will maintain control of the Senate, giving them leverage to block efforts at repeal.

If you want to wager that the demand for pharmaceuticals and medical devices will remain strong, consider buying a health care mutual fund. But keep in mind that health care funds follow different strategies.

Some funds emphasize fast-growing biotech and drug companies, while other choices take a tamer approach, focusing on stable companies with slower growth and modest valuations. Funds in the growth camp include Alger Health Sciences (AHSAX), Eaton Vance Worldwide Health Sciences (ETHSX), and T. Rowe Price Health Sciences (PRHSX).

Funds that focus on pharmaceutical giants and other stable choices include Live Oak Health Sciences (LOGSX), Schwab Health Care (SWHFX) and Vanguard Health Care (VGHCX).

A solid choice in the growth camp is Eaton Vance Worldwide Health Sciences. During the past five years, the fund returned 6.1% annually, outpacing 68% of peers. Investors seeking a more mild-mannered fund should consider Live Oak Health Sciences, which returned 6.3% annually.

While Eaton Vance and Live Oak have had similar returns, the managers of the two funds hold very different views. Sam Isaly, Eaton Vance's portfolio manager, argues that the future is bright for biotechnology companies.

Mark Oelschlager of Live Oak says that many of the strong performers are too expensive for his tastes. Instead, he is focusing on unloved device makers and pharmaceutical distributors.

Seeking to find the best growth in the health sector, Isaly has 20% of his assets in biotechnology. He says that the biotechnology companies are proving to be powerful innovators, accounting for half of all new drug approvals in the U.S.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $117.34 -0.81%
FB $107.12 2.76%
GOOG $767.04 3.29%
TSLA $237.19 3.01%
YHOO $33.71 -0.30%


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs